Relay Therapeutics, Inc.(RLAY)Earnings, Financials & Key RatiosRelay Therapeutics, Inc. (RLAY) stock price & volume — 10-year historical chart
Relay Therapeutics, Inc. (RLAY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Relay Therapeutics, Inc. (RLAY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.41vs $0.35-17.1% | $3Mvs $6M-46.2% |
| Q1 2026 | Feb 26, 2026 | $0.32vs $0.38+15.8% | $7Mvs $5M+41.0% |
| Q4 2025 | Nov 6, 2025 | $0.43vs $0.39-10.3% | —vs $5M |
| Q3 2025 | Aug 7, 2025 | $0.41vs $0.49+16.3% | $677,000vs $14,290+4637.6% |
Recent stock market news and headlines for Relay Therapeutics, Inc. (RLAY)
Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.
Key metrics vs top competitors for Relay Therapeutics, Inc. (RLAY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.74 | $3.73B | -12.26 | 53.44% | -1800.58% | -41.12% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $8.59 | $554.24M | -6.71 | -0.3% | -247.54% | -44.39% | — | |
| $42.13 | $4.88B | -13.21 | — | — | -71.31% | — | |
| $18.36 | $5.71B | -41.73 | — | — | -77.01% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — |
Relay Therapeutics, Inc. (RLAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Relay Therapeutics, Inc. (RLAY) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 27, 2026·SEC
Mar 16, 2026·SEC
Get notified when RLAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Relay Therapeutics, Inc. (RLAY) stock FAQ — growth, dividends, profitability & financials explained
Relay Therapeutics, Inc. (RLAY) reported $10.7M in revenue for fiscal year 2025.
Relay Therapeutics, Inc. (RLAY) grew revenue by 53.4% over the past year. This is strong growth.
Relay Therapeutics, Inc. (RLAY) reported a net loss of $272.7M for fiscal year 2025.
Relay Therapeutics, Inc. (RLAY) has a return on equity (ROE) of -41.1%. Negative ROE indicates the company is unprofitable.
Relay Therapeutics, Inc. (RLAY) had negative free cash flow of $213.4M in fiscal year 2025, likely due to heavy capital investments.
